-
Syria site infrastructure 'consistent with nuclear reactor': IAEA
-
Man City set to sign Fernandez for record fee, Ndiaye on deadline day
-
Juventus sign Woltemade, Sarr on loan from Premier League
-
Back-to-school in Cuba a grim day with shortages of everything
-
US strikes Iran in latest tit-for-tat attacks
-
Canadian minister says Russia's G20 presence sparked 'discomfort'
-
China's Xi arrives in Egypt as US sanctions threat looms over Iran links
-
IMF reaches agreement with Senegal on new $2.2 bn loan programme
-
Car bomb at Colombian police station kills one, injures 11
-
Germany blames Russia for airport drone incident, hits back with sanctions
-
Rain delays start of play on US Open
-
Iran president urges return to truce, hails Russian support
-
Man City agree blockbuster deal to sign Chelsea star Fernandez: reports
-
Aster and World Liberty Financial Launch USD1 RWA Boost: Phase 1, Offering 125M $WLFI + 6.25M USD1 in Rewards
-
Alkemya Metacore Secures $50M via Tokenised Equity to Scale Nickel Energy and Security Tech
-
Tronchon sprints to Vuelta stage 10 win, Mas keeps red jersey
-
Man City chase Fernandez, Arsenal sell Jesus on deadline day
-
Germany defender Rudiger announces international retirement
-
EU says Russian 'hybrid attacks' won't halt aid to Ukraine
-
Musk defends AI data centers, slams EU rules at G20
-
Explosives used in sabotage attack on German power lines
-
Activists blame Kenya for Ugandan opposition figure's plight
-
Nepali families hold symbolic funerals for missing after floods
-
Iran president offers US olive branch, hails Russian support
-
Newcastle sign Lille forward Fernandez-Pardo
-
TrustFinance Community Choice Awards 2026 Opens Global Voting
-
Even at Elysee, phones are handed in, Macron tells French pupils
-
Nepal disaster a climate 'warning signal': foreign minister
-
Chelsea agree to sign Atalanta's Ahanor, with Palace loan for this season
-
France winger Diaby returns to Leverkusen until 2031
-
Chelsea sign Atalanta's Ahanor and loan him to Palace
-
Barcelona confirm Jesus arrival from Arsenal
-
UK chalks up hottest summer on record for second year running
-
EU official says it's not time to 'normalize' Russia at G20 finance talks
-
China's Xi visits Egypt as US sanctions threat looms over Iran links
-
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
-
RISE Robotics Awarded $100,000 MassVentures Grant to Accelerate Commercialization of Beltdraulic Technology
-
TrendEadvisor Launches Global Multi-Asset Platform Combining Online Investing with Social Trading
-
Global bond sell-off deepens on inflation concerns
-
India's top court drops criminal cases against protesters
-
Germany's far-right AfD promises 'boom' but economists fear worst
-
Philippine couple married in hip-deep floodwaters
-
Former England captain Stokes signs for Adelaide Strikers
-
Villa sign Senegal winger Mbaye from PSG
-
Pakistan selector and ex-captain Misbah resigns after coach sacked
-
Former Peru minister last-minute contender for UN labour agency helm
-
Shein flattens on Hong Kong debut facing global headwinds
-
Messi legacy will 'live forever', says Beckham
-
Eurozone inflation hits three-year high at 3.3% in August
-
'Literally tasting the smoke': Malaysians suffer as haze worsens
Harte Hanks Acquires Exclusive Rights to License ADS Data Direct's Premier Medical Ailment Database
Strategic Licensing Rights Strengthen Harte Hanks' Leadership in Compliant, High-Precision Healthcare Marketing
CHELMSFORD, MA / ACCESS Newswire / June 2, 2025 / Harte Hanks (NASDAQ:HHS), a global leader in customer experience and data-driven marketing, today announced that it has obtained exclusive rights to license ADS Data Direct's (ADS) industry-leading Medical Ailment Database, with limited client exceptions. This transformative undertaking positions Harte Hanks as the controller of one of the most comprehensive, HIPAA-compliant health data assets available in the market, delivering unmatched value to healthcare marketers.
ADS's Medical Ailment Database, sourced through the Healthier Me Today platform, provides access to 100% triple opt-in consumers who have self-identified as living with specific health conditions across more than 200 ailment categories. This valuable data asset enhances Harte Hanks' ability to deliver superior targeting precision, campaign performance, and compliance assurance for clients in the pharmaceutical, medical device, and broader healthcare sectors.
"The exclusive licensing right to this high-integrity database is a strategic milestone for Harte Hanks, deepening our commitment to delivering unparalleled data solutions that empower healthcare and health-related marketers," said Teresa Gavin, VP of Data Solutions at Harte Hanks. "We are now better positioned than ever to help our clients engage the right consumers-ethically, effectively, and with measurable impact."
The Medical Ailment Database is distinguished by its depth and reliability, capturing self-reported health data through rigorous HIPAA-compliant processes on the Healthier Me Today platform. It is purpose-built to support campaigns targeting individuals managing conditions such as diabetes, arthritis, heart disease, mental health disorders, and many more.
ADS is a premium provider of precision-targeted marketing solutions, offering proprietary data assets that drive scalable lead generation and engagement strategies across digital, mobile, email, and direct mail channels.
"Harte Hanks' licensing rights to our flagship health database reflects their vision and leadership in data-driven marketing," said Eric Nelson, President & Managing Partner of ADS Data Direct. "We are confident that their expertise and strategic focus will unlock the full potential of this asset, delivering exceptional value to healthcare and health-related marketers."
For media inquiries or to learn more about the Medical Ailment Database, please contact:
Cindy Stein
Global Head of Marketing
Harte Hanks
[email protected]
www.HarteHanks.com
SOURCE: Harte Hanks, Inc.
View the original press release on ACCESS Newswire
M.O.Allen--AT